Vaccines for treating sars infections in cancer patients
AssigneeCity of Hope
InventorsJianhua Yu, Michael A. Caligiuri
Life of this patent
Estimating the term…
Abstract
Provided herein are, inter alia, compositions including recombinant oncolytic herpes simplex viruses that express SARS-CoV spike (S) protein and viral vectors including nucleic acid sequences encoding SARS-CoV S protein. The compositions are useful for eliciting antibodies to SARS-CoV. The compositions are contemplated to be particularly useful for methods of treating and preventing SARS coronavirus infections in cancer patients.
Claims35
A recombinant oncolytic herpes simplex virus capable of expressing a SARS-CoV spike (S) protein.
(canceled)
(canceled)
(canceled)
A recombinant oncolytic herpes simplex virus particle comprising a SARS-CoV spike (S) protein on a surface of the particle.
(canceled)
A fusion protein comprising a SARS-CoV spike (S) protein, a glycoprotein D transmembrane domain, and a glycoprotein D intracellular domain.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.